Two former MedImmune execs out at AstraZeneca unit

AstraZeneca PLC has parted ways with Scott Carmer and Tim Gray, two formerMedImmune executives who most recently held top positions in AZ's newly created specialty care division, the pharmaceutical giant confirmed this week.Both Carmer and Gray left the company on Nov. 8, according to AstraZeneca spokeswoman Michele Meixell. She declined to elaborate on the circumstances of their exit and would not say whether or not they were let go.The two departures are the latest in ongoing structural changes at the Gaithersburg biotech, but are no less complex to explain. London-based AstraZeneca acquired MedImmune in 2007 to serve as its U.S.-based biologics arm and, earlier this year, split the local biotech into three divisions as part of a broader shake-up. MedImmune's commercial operations were folded into a new AstraZeneca specialty care unit, led by Carmer.The former Genentech Inc. exec had first joined MedImmune in 2010 as executive vice president of commercial operations, where he oversaw sales and marketing of infant respiratory product Synagis and influenza vaccine FluMist.Gray, formerly chief financial officer of MedImmune, most recently headed up finance under the specialty care division.Neither could be reached for comment.AstraZeneca has yet to realize its dreams of turning MedImmune into a launching pad for blockbuster drugs, and the changes this year underscore the extent to which London is depending on Gaithersburg ...
Source: PharmaGossip - Category: Pharma Commentators Authors: Source Type: blogs